Phoenix Financial’s BridgeBio Pharma BBIO Stock Holding History

Phoenix Financial’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,851	Closed	-$209K	–	471
2025 Q2	$209K	Buy	+4,851	New	+$176K	﹤0.01%	400

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Phoenix Financial's BBIO Position: Q3 2025 in Review

Phoenix Financial sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 4,851 shares — an estimated $209K sold.

Phoenix Financial first reported a position in BBIO in Q2 2025 and held it in 1 quarter. The position peaked at $209K in Q2 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

Phoenix Financial reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
Phoenix Financial sold 4,851 BridgeBio Pharma shares in Q3 2025, an estimated $209K.
Phoenix Financial first reported a position in BridgeBio Pharma in Q2 2025 and held it in 1 quarter.
Phoenix Financial's BridgeBio Pharma position peaked at $209K in Q2 2025.
392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Phoenix Financial's 13F filing for Q3 2025, filed 3 Nov 2025.